A Phase 3 interventional study of Entecavir and Lamivudine in Pediatric Immuno-Tolerant Chronic Hepatitis B, sponsored by Hoffmann-La Roche. Completed at 25 sites in 12 countries. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-08-24.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing entecavir in Hepatitis B, Chronic — 3 open to participants now, 3 under way, none of them phase 3. entecavir · Hepatitis B, Chronic.
Among the 64 studies testing entecavir in Hepatitis B, Chronic, this one is the 44th largest by enrollment of the 61 interventional ones that give a count, is one of 2 that started in 2014, is one of 13 in phase 3, and was the 44th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →3 of the 64 studies testing entecavir in Hepatitis B, Chronic are open now, in 1 country. Recruiting first, the newest first:
Ascentage Pharma Group Inc. · Sites in China
Ages 18+
Qing-Lei Zeng
Ages 3–6
Qing-Lei Zeng
Ages 3–6
By country, each count listing its studies:
entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 3 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 10 · Phase 3 13 · Phase 4 33
First in 2001; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is below the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 109 across the 61 interventional studies. Of the 40 that completed or were terminated, 15 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 64 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
46 studies in Hepatitis B, Chronic by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 45 finished, 25 (56%) have results posted.
Among the 46 studies in Hepatitis B, Chronic by Hoffmann-La Roche, this one is the 19th largest by enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2014, is one of 7 in phase 3, and was the 34th registered.
Hoffmann-La Roche’s Hepatitis B, Chronic studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 64 studies testing entecavir in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 46 in Hepatitis B, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This randomized, controlled, parallel group, open-label multicenter study will evaluate the efficacy and safety of a combination of pegylated interferon alfa-2A (Pegasys) plus lamivudine or entecavir compared with an untreated control group in participants with HBeAg positive CHB in the immune tolerant phase. NOTE: STUDY RECRUITMENT HAS BEEN TERMINATED
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive lamivudine or entecavir alone for 8 weeks followed by peg-IFN-alfa-2A in combination with lamivudine or entecavir for 48 weeks.
Drug: Entecavir · Drug: Lamivudine · Drug: Pegylated Interferon Alfa-2A
Untreated control participants will be observed up to 80 weeks.
Participants will receive Peginterferon Alfa 2A subcutaneously once weekly with dosing based on body surface area (BSA) categories for 48 weeks.
Drug: Pegylated Interferon Alfa-2A
Participants will receive entecavir, either as a film-coated tablet or oral solution, once daily at a dose of 0.015 milligrams per kilogram (mg/kg) (maximum daily dose of 0.5 mg).
Participants will receive lamivudine, either as a film-coated tablet or oral solution, once daily at a dose of 3 mg/kg (maximum daily dose of 100 mg).
Participants will receive pegylated interferon-alfa-2A at a body surface area (BSA) based dose of 180 micrograms per 1.73 square meter (mcg/1.73m\^2) BSA.
Also known as: Pegasys, Peg-IFN-Alfa-2A
Percentage of Participants With Loss of Hepatitis B Surface Antigen (HBsAg) at 24 Weeks Post-End of Treatment/End of Untreated Observation
This endpoint is defined as loss of HBsAg at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80). The percentage of responders (response rate) and 95% CI (using the Clopper-Pearson method) for the response rate are presented for each group.
Time frame: 24 weeks post-treatment/at the end of untreated observation (Week 80)
Percentage of Participants With Loss of HBsAg
This endpoint is defined as loss of HBsAg at 1 year post-treatment in the treated group. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.
Time frame: 1 year post-end of treatment (End of treatment = Week 56)
Percentage of Participants With Loss of Hepatitis B Virus Envelope Antigen (HBeAg)
This endpoint is defined as loss of HBeAg at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80) and at 1 year post-end of treatment in the treated group. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.
Time frame: 24 weeks post-treatment /end of untreated observation (Week 80), and 1 year post-end of treatment (End of treatment = Week 56)
Percentage of Participants With Seroconversion to Hepatitis B Surface Antibody (Anti-HBs), Defined as Loss of HBsAg and Presence of Anti-HBs
This endpoint measures the seroconversion to anti-HBs defined as loss of HBsAg and presence of anti-HBs at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80) and at 1 year post-end of treatment in the treated group. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.
Time frame: 24 weeks post-treatment /end of untreated observation (Week 80), and 1 year post-end of treatment (End of treatment = Week 56)
Percentage of Participants With Seroconversion to Hepatitis B Envelope Antibody (Anti-HBe), Defined as Loss of HBeAg and Presence of Anti-HBe
This endpoint measures the seroconversion to anti-HBe defined as loss of HBeAg and presence of anti-HBe at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80) and at 1 year post-end of treatment in the treated group. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.
Time frame: 24 weeks post-treatment /end of untreated observation (Week 80), and 1 year post-end of treatment (End of treatment = Week 56)
Percentage of Participants With Different Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Levels (Less Than [<] 20,000 International Units Per Milliliter [IU/mL], < 2000 IU/mL, or Undetectable HBV DNA)
This endpoint measures different HBV DNA levels (\<20000 IU/mL, \<2000 IU/mL and undetectable) measured by PCR or hybridization at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80) and at 1 year post-treatment in the treated group. HBV-DNA undetectable is defined as \<29 IU/mL. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.
Time frame: 24 weeks post-treatment /end of untreated observation (Week 80), and 1 year post-end of treatment (End of treatment = Week 56)
Change From Baseline in HBV DNA Levels in the Peg-INF-Alfa-2A (Treated) Arm
This outcome measure presents HBV DNA levels measured at defined time points from baseline in the Peg-INF-Alfa-2A + Lamivudine or Entecavir arm.
Time frame: Baseline, Week 8, 20, 32, 44, 56, Follow up Week 4 and 24
Change From Baseline in HBV DNA Levels in the Untreated Control Participants
This outcome measure presents HBV DNA levels measured at defined time points from baseline in the Untreated Control arm.
Time frame: Baseline, Week 32, 56 and end of untreated observation (Week 80)
Percentage of Participants With Combined Response for HBeAg Seroconversion (Defined as Loss of HBeAg and Presence of Anti-HBe) and HBV DNA Levels <20,000 IU/mL
This endpoint measures the combined response for HBeAg Seroconversion and HBV DNA Levels \<20,000 IU/mL at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80) and at 1 year post-end of treatment in the treated group. The HBeAg is defined as loss of HBeAg and presence of anti-HBe. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.
Time frame: 24 weeks post-treatment /end of untreated observation (Week 80), and 1 year post-end of treatment (End of treatment = Week 56)
Percentage of Participants With Combined Response for HBeAg Seroconversion (Defined as Loss of HBeAg and Presence of Anti-HBe) and HBV DNA Levels <2000 IU/mL
This endpoint measures the combined response for HBeAg Seroconversion and HBV DNA Levels \<2000 IU/mL at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80) and at 1 year post-end of treatment in the treated group. The HBeAg is defined as loss of HBeAg and presence of anti-HBe. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.
Time frame: 24 weeks post-treatment /end of untreated observation (Week 80), and 1 year post-end of treatment (End of treatment = Week 56)
Percentage of Participants With Adverse Events (AEs)
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
Time frame: Baseline up to 24 weeks post-treatment/end of untreated observation (Week 80)
Percentage of Participants With AEs Leading to Dose Modification or Interruption
This endpoint measures AEs and lab abnormalities leading to dose interruption or dose modification. Does modification included dose reduced, dose increased or drug interrupted. Adverse events included laboratory abnormalities reported as adverse events.
Time frame: Baseline up to 24 weeks post-end of treatment
Serum Concentration of Peg-INF-Alfa-2A
The serum concentration of Peg-INF-Alfa-2A was measured in picogram/milliliter.
Time frame: At Weeks 12, 16, 20, 32, 44, 56
The study began as a single-site, three arm IST and was subsequently adapted as a multi-center, two arm study, conducted at 22 sites in Malaysia, Taiwan, Australia, Belgium, Germany, United Kingdom, Italy, Romania, Russian Federation, Turkey, Ukraine and the U.S. Enrolment was stopped prematurely, at which time 62 participants had been enrolled.
| Milestone | Peg-IFN-Alfa-2A + Lamivudine or Entecavir | Untreated Control Participants | Peg-INF-Alfa-2A Monotherapy |
|---|---|---|---|
| Started | 26 | 33 | 3 |
| Completed | 23 | 25 | 3 |
| Not completed | 3 | 8 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 8 | 0 |
This endpoint is defined as loss of HBsAg at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80). The percentage of responders (response rate) and 95% CI (using the Clopper-Pearson method) for the response rate are presented for each group.
| Percentage of Participants | Peg-IFN-Alfa-2A + Lamivudine or Entecavir | Untreated Control Participants |
|---|---|---|
| Percentage of Participants With Loss of Hepatitis B Surface Antigen (HBsAg) at 24 Weeks Post-End of Treatment/End of Untreated Observation | 3.8 (0.10 to 19.64) | 0 (0.00 to 10.58) |
This endpoint is defined as loss of HBsAg at 1 year post-treatment in the treated group. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.
| Percentage of Participants | Peg-IFN-Alfa-2A + Lamivudine or Entecavir |
|---|---|
| Percentage of Participants With Loss of HBsAg | 3.8 (0.10 to 19.64) |
This endpoint is defined as loss of HBeAg at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80) and at 1 year post-end of treatment in the treated group. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.
| Percentage of Participants | Peg-IFN-Alfa-2A + Lamivudine or Entecavir | Untreated Control Participants |
|---|---|---|
| 24 Weeks post-treatment/Week 80 | 3.8 (0.10 to 19.64) | 12.1 (3.40 to 28.20) |
| 1 year post-end of treatment | 11.5 (2.45 to 30.15) | — |
This endpoint measures the seroconversion to anti-HBs defined as loss of HBsAg and presence of anti-HBs at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80) and at 1 year post-end of treatment in the treated group. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.
| Percentage of Participants | Peg-IFN-Alfa-2A + Lamivudine or Entecavir | Untreated Control Participants |
|---|---|---|
| 24 Weeks post-treatment/Week 80 | 3.8 (0.10 to 19.64) | 0.0 (0.00 to 10.58) |
| 1 year post-end of treatment | 3.8 (0.10 to 19.64) | — |
This endpoint measures the seroconversion to anti-HBe defined as loss of HBeAg and presence of anti-HBe at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80) and at 1 year post-end of treatment in the treated group. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.
| Percentage of Participants | Peg-IFN-Alfa-2A + Lamivudine or Entecavir | Untreated Control Participants |
|---|---|---|
| 24 Weeks post-treatment/Week 80 | 0.0 (0.00 to 13.23) | 9.1 (1.92 to 24.33) |
| 1 year post-end of treatment | 7.7 (0.95 to 25.13) | — |
This endpoint measures different HBV DNA levels (\<20000 IU/mL, \<2000 IU/mL and undetectable) measured by PCR or hybridization at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80) and at 1 year post-treatment in the treated group. HBV-DNA undetectable is defined as \<29 IU/mL. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.
| Percentage of Participants | Peg-IFN-Alfa-2A + Lamivudine or Entecavir | Untreated Control Participants |
|---|---|---|
| HBV-DNA <20000 IU/mL at follow up Week 24/Week 80 | 7.7 (0.95 to 25.13) | 12.1 (3.40 to 28.20) |
| HBV-DNA <2000 IU/mL at follow up Week 24/Week 80 | 7.7 (0.95 to 25.13) | 12.1 (3.40 to 28.20) |
| HBV-DNA Undetectable at follow up Week 24/Week 80 | 0.0 (0.00 to 13.23) | 6.1 (0.74 to 20.23) |
| HBV-DNA <20000 IU/mL 1 year post-end of treatment | 15.4 (4.36 to 34.87) | — |
| HBV-DNA <2000 IU/mL 1 year post-end of treatment | 7.7 (0.95 to 25.13) | — |
| HBV-DNA Undetectable 1 year post-end of treatment | 0.0 (0.00 to 13.23) | — |
This outcome measure presents HBV DNA levels measured at defined time points from baseline in the Peg-INF-Alfa-2A + Lamivudine or Entecavir arm.
| log10 IU/mL | Peg-IFN-Alfa-2A + Lamivudine or Entecavir |
|---|---|
| Baseline | 8.02 ± 0.93 |
| Week 8 | 4.74 ± 1.01 |
| Week 20 | 3.54 ± 0.81 |
| Week 32 | 2.56 ± 0.84 |
| Week 44 | 2.15 ± 0.70 |
| Week 56 | 2.21 ± 0.90 |
| Fu Week 4 | 4.34 ± 2.65 |
| Fu Week 24 | 7.31 ± 1.99 |
This outcome measure presents HBV DNA levels measured at defined time points from baseline in the Untreated Control arm.
| log10 IU/mL | Untreated Control Participants |
|---|---|
| Baseline | 8.22 ± 1.07 |
| Week 32 | 8.29 ± 0.97 |
| Week 56 | 7.57 ± 1.96 |
| Week 80 | 7.24 ± 2.58 |
This endpoint measures the combined response for HBeAg Seroconversion and HBV DNA Levels \<20,000 IU/mL at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80) and at 1 year post-end of treatment in the treated group. The HBeAg is defined as loss of HBeAg and presence of anti-HBe. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.
| Percentage of Participants | Peg-IFN-Alfa-2A + Lamivudine or Entecavir | Untreated Control Participants |
|---|---|---|
| 24 Weeks post-treatment/Week 80 | 0.0 (0.00 to 13.23) | 9.1 (1.92 to 24.33) |
| 1 year post-end of treatment | 7.7 (0.95 to 25.13) | — |
This endpoint measures the combined response for HBeAg Seroconversion and HBV DNA Levels \<2000 IU/mL at 24 weeks post-treatment (follow-up Week 24)/end of untreated observation (Week 80) and at 1 year post-end of treatment in the treated group. The HBeAg is defined as loss of HBeAg and presence of anti-HBe. The 95% Confidence Interval of response rate is calculated by Clopper-Pearson method.
| Percentage of Participants | Peg-IFN-Alfa-2A + Lamivudine or Entecavir | Untreated Control Participants |
|---|---|---|
| 24 Weeks post-treatment/Week 80 | 0.0 (0.00 to 13.23) | 9.1 (1.92 to 24.33) |
| 1 year post-end of treatment | 7.7 (0.95 to 25.13) | — |
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
| Percentage of Participants | Peg-IFN-Alfa-2A + Lamivudine or Entecavir | Untreated Control Participants |
|---|---|---|
| With at least one Non-Serious AE | 92.3 | 45.5 |
| With at least one Serious Adverse Event (SAE) | 0 | 3.0 |
This endpoint measures AEs and lab abnormalities leading to dose interruption or dose modification. Does modification included dose reduced, dose increased or drug interrupted. Adverse events included laboratory abnormalities reported as adverse events.
| Percentage of Participants | Peg-IFN-Alfa-2A + Lamivudine or Entecavir |
|---|---|
| Percentage of Participants With AEs Leading to Dose Modification or Interruption | 23.0 |
The serum concentration of Peg-INF-Alfa-2A was measured in picogram/milliliter.
| pg/mL | Peg-IFN-Alfa-2A + Lamivudine or Entecavir |
|---|---|
| Week 12 Predose | 8430 ± 6090 |
| Week 16 Predose | 16300 ± 10100 |
| Week 20 Predose | 13800 ± 8740 |
| Week 32 Predose | 14900 ± 7710 |
| Week 32 24-48h Post-dose | 22700 ± 6070 |
| Week 32 72-96h Post-dose | 23000 ± 4900 |
| Week 32 168h Post-dose | 19300 ± 5880 |
| Week 44 Predose | 21900 ± 14200 |
| Week 56 Predose | 25400 ± 13100 |
Collected over From Baseline up to 1 year post-end of treatment in the treated arm; From Baseline to end of untreated observation (Week 80) in the untreated group [up to clinical cut-off date 29 Jan 2020]. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Peg-IFN-Alfa-2A + Lamivudine or Entecavir | 0/26 (0%) | 0/26 (0%) | 21/26 (80.8%) |
| Untreated Control Participants | 0/33 (0%) | 1/33 (3%) | 10/33 (30.3%) |
| Peg-INF-Alfa-2A Monotherapy | 0/3 (0%) | 0/3 (0%) | — |
| Event | Peg-IFN-Alfa-2A + Lamivudine or Entecavir | Untreated Control Participants | Peg-INF-Alfa-2A Monotherapy |
|---|---|---|---|
| PHARYNGITISInfections and infestations | 0/26 | 1/33 | 0/3 |
| DEHYDRATIONMetabolism and nutrition disorders | 0/26 | 1/33 | 0/3 |
| Event | Peg-IFN-Alfa-2A + Lamivudine or Entecavir | Untreated Control Participants | Peg-INF-Alfa-2A Monotherapy |
|---|---|---|---|
| HEADACHENervous system disorders | 14/26 | 0/33 | — |
| PYREXIAGeneral disorders | 11/26 | 0/33 | — |
| FATIGUEGeneral disorders | 5/26 | 0/33 | — |
| NAUSEAGastrointestinal disorders | 4/26 | 1/33 | — |
| ABDOMINAL PAIN UPPERGastrointestinal disorders | 3/26 | 3/33 | — |
| VOMITINGGastrointestinal disorders | 3/26 | 1/33 | — |
| PAINGeneral disorders | 3/26 | 0/33 | — |
| NASOPHARYNGITISInfections and infestations | 3/26 | 1/33 | — |
| DIZZINESSNervous system disorders | 3/26 | 0/33 | — |
| EPISTAXISRespiratory, thoracic and mediastinal disorders | 3/26 | 1/33 | — |
Due to the low participant number (n=3) in the Peg-INF-Alfa-2A Monotherapy arm, data is not presented in this summary for this arm to avoid participant re-identification as well as in consideration of any summary statistics would be misleading, therefore the three participants were presented in listings in the study report.
| Age, Continuous(Years) | Peg-IFN-Alfa-2A + Lamivudine or Entecavir | Untreated Control Participants | Peg-INF-Alfa-2A Monotherapy | Total |
|---|---|---|---|---|
| Mean | 11.9 ± 3.2 | 10.9 ± 3.7 | — | 11.3 ± 3.5 |
| Sex: Female, Male(Participants) | Peg-IFN-Alfa-2A + Lamivudine or Entecavir | Untreated Control Participants | Peg-INF-Alfa-2A Monotherapy | Total |
|---|---|---|---|---|
| Female | 16 | 14 | — | 30 |
| Male | 10 | 19 | — | 29 |
| Race/Ethnicity, Customized(Participants) | Peg-IFN-Alfa-2A + Lamivudine or Entecavir | Untreated Control Participants | Peg-INF-Alfa-2A Monotherapy | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | — | 1 |
| Not Hispanic or Latino | 25 | 33 | — | 58 |
| Race/Ethnicity, Customized(Participants) | Peg-IFN-Alfa-2A + Lamivudine or Entecavir | Untreated Control Participants | Peg-INF-Alfa-2A Monotherapy | Total |
|---|---|---|---|---|
| Asian | 11 | 11 | — | 22 |
| Black or African American | 4 | 2 | — | 6 |
| Multiple | 2 | 0 | — | 2 |
| Other | 0 | 3 | — | 3 |
| White | 9 | 17 | — | 26 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from Jun 2014 to primary completion in Jan 2020, 67 months.
Results were first posted in Aug 2020, 6 months after primary completion.
Of 24 phase 3 interventional studies under Hepatitis B, Chronic, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 47. This study's 67 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Entecavir · Lamivudine · Peginterferon alfa-2a